Please login to the form below

2022: What next after digital transformation?

After the inevitable push into the virtual world amplified by COVID-19 and robust efforts in the name of digital transformation across the healthcare sector, 2022 is set to be the year of digital integration. We’re past tactical plans disguised as strategies and merely replicating content across channels. A new approach by the pharmaceutical industry is required to respond to the new digital world. Hanover’s Health’s Solveig Veerkamp explains how a truly hybrid, holistic approach is essential to respond to the most important health challenges to come.

Until two years ago, including some digital elements into marketing and communications sufficed for pharmaceutical organisations to feel content with their progress towards digital transformation. At the time, many brands were still dabbling on the surface of the digital world by creating social media strategies, treatment-centric chatbots or spreading thought leadership across platforms - and this sufficed.

Today, digital and social media are undeniably embedded in our lives. In January this year, Statista reported that 59.5% of the world’s population were actively online[1], and each of us has personally witnessed (however actively or passively) LinkedIn becoming the new Facebook, with activity increasing astonishingly over the last few months.

Digital media has made boundaries blurry between our personal and professional lives. Organisations and individuals are trying to integrate newly acquired virtual knowledge and habits, and are building the hybrid world that tech has been predicting for years. That crossover is something to capitalise online by creating ecosystems that allow for seamless transitions between the digital and the real world.

As well as the accelerated move into an increasingly hybrid world, business and corporate news are inserted into the mainstream, with strong links with current affairs and the pharmaceutical sector leading several big topics that will define our future globally – from heated debates about the NHS to data ethics and AI, from wearable tech governance to telemedicine and discussions about accelerated access of innovation to help patients worldwide.

Online news consumption is indisputably widespread across websites, apps, podcasts and social media. Now more than ever, the pharmaceutical industry needs to think digital first. We need to go from digital transformation to digital integration.

A hybrid world offers a wide array of possibilities and demands strategic thinking. We are past tactical plans disguised as strategies and merely replicating content across channels. Everyone is online and brands interact with all of their target audiences on digital platforms. The healthcare sector is at the centre of the agenda and each organisation needs to ask itself why it communicates and what for.

For successful digital campaigns and for long-term online presence, organisations need to demonstrate their purpose on every platform consistently. More so in the case of the healthcare sector, where patients are at the heart of everything. What pharmaceutical companies say and how they say it is under scrutiny more than ever in the media and across channels, and consistency is vital.

Users know what good looks like. They have experience with many types of organisations and individuals. And they have expectations you need to manage.

No matter the number of platforms an organisation is present on, it is essential to adopt a truly hybrid, holistic approach to respond to a world where the online and offline connect ever more seamlessly. We need to engage with our audiences fluidly and meaningfully, ensuring a sustained approach with a mid- and long-term vision.

To get started, here are three essential elements for pharmaceutical companies to consider for their integrated communications efforts:

  1. Audience-centricity: Break down your target audiences and get to know them, what they care about and their concerns. Remember to consider them as 360 people: they’re professionals, they might be parents/siblings/grandchildren, they care about causes, they will also have hobbies and other interests.
  2. Valuable content: What value are you providing to your audiences, and is there anything else you could add (or take out) to increase that value? Understanding who you are as a company and where you can provide value in terms of communications is key to leverage your strengths.
  3. Platform map: Map out the different platforms and channels where you have presence, and see how they connect with each other, while looking at the different user journeys you are creating as an ecosystem. Is it clear? Does it make sense for your different target audiences? How is it supporting them and your purpose?

Having strong strategic foundations will set you up for success: think digital first and go from digital transformation into digital integration. If the former enabled you to begin using digital and social platforms, the next step is to strengthen them and build a hybrid ecosystem that truly represents your company and what it stands for, across every single online and offline channel.

[1] Statista, “Global digital population as of January 2021”, 2021


9th November 2021

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

2022: What next after digital transformation?
After the inevitable push into the virtual world amplified by COVID-19 and robust efforts in the name of digital transformation across the healthcare sector, 2022 is set to be the year of digital integration. We’re past tactical plans disguised as strategies and merely replicating content across channels. A new approach by the pharmaceutical industry is required to respond to the new digital world. Hanover’s Health’s Solveig Veerkamp explains how a truly hybrid, holistic approach is essential to respond to the most important health challenges to come.
Hanover Communications
What next for health? The weeks that have seen a whirlwind in Whitehall.
It won’t have escaped your attention that the debris from the PM’s recent reshuffle has left industry and policy makers with more questions than it has answers. This comes at a critical time for the healthcare system, particularly ahead of the winter period. ‘Levelling Up’ is the agenda. Covid has highlighted the extent of health inequalities across the UK. In her latest blog, Ursula Ritz considers the implications of the change of senior leadership at DHSC and NHSE for existing priorities, including for those of us committed to ensuring the best and innovative drugs make it to patients.
Press Releases
Will most electronic consumer goods turn into medical devices after the MDR?
In her latest blog, Hanover Brussels Aleksandra Lugovic explores concerns over the rising coexistence of health apps and electronic goods that may become medical devices according to the EU Regulation.
Hanover Communications
What do NHS changes and the Life Sciences Vision mean for medicines?
With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.
Hanover Communications
Addressing the Gendered Health Data Gap
The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.
Hanover Communications
Greener healthcare - a shared challenge
At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.
Hanover Communications